Matthew Barcus
Stock Analyst at Chardan Capital
(0)
# 3145
Out of 5,218 analysts
35
Total ratings
22.73%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Zura Bio | Maintains: Buy | 14 12 | 2.29 | 424.02% | 2 | Nov 8, 2024 | |
uniQure | Maintains: Buy | 45 27 | 15.35 | 75.9% | 4 | Jun 22, 2023 | |
Xilio Therapeutics | Reiterates: Buy | 7 | 0.98 | 614.29% | 3 | May 30, 2023 | |
Immunovant | Maintains: Strong Buy | 21 32 | 26.32 | 21.58% | 4 | May 23, 2023 | |
Purple Biotech | Reiterates: Buy | 220 | 3.81 | 5674.28% | 3 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 144 126 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 9 | 2.84 | 216.9% | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 9 8 | 12.59 | -36.46% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | 0.19 | 1478.95% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 21, 2022 |